Skip to content

N/A - TOCITAKA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-005039-26-FR
Enrollment
15
Registered
2015-06-24
Start date
2014-03-10
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.0 Level: LLT Classification code 10043098 Term: Takayasu's disease System Organ Class: 100000004866

Interventions

Trade Name: RoActemra Product Name: RoActemra Product Code: EMEA/H/C/000955 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Concent

Sponsors

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026